



A
Cell Count (CD3+)
2.0×10^6
1.5×10^6
1.0×10^6
5.0×10^5
0.0
Naive
Tumor-Bearing Control
DC Vaccine
*
B
% Activated Lymphocytes
80
60
40
20
0
Tumor-Bearing Control
DC Vaccine
*
C
Percent survival
100
75
50
25
0
0
20
40
60
Days
Control
DC Vax


FIGS. 1A-1C


% Thy1.2-Ly6C+
80
60
40
20
0
**
**
Naive
Tumor-Bearing Control
DC Vaccine
A
% PDL1+/Thy1.2-Ly6C+
100
80
60
40
20
0
**
*
Naive
Tumor-Bearing Control
DC Vaccine
B

FIGS. 2A-2B


% CD8+
% Activated Lymphocytes
% Thy1.2+ Lyt6C+
% PDL1 +/ Thy1.2+ Lyt6C+
% Activated Lymphocytes
Percent survival
Days
No Tx
anti-PD-1
DC Vaccine
anti-PD-1 Ab + DC Vaccine
Percent survival
Days
No Tx
anti-PD-1 Ab+ DC Vaccine

FIGS. 3A-3G


Count
1.2K
900
600
300
0
Pre-Lysate
Post-Lysate
10^0 10^1 10^2 10^3 10^4 10^5
PDL1 (PerCP-Cy5.5)
A
MFI
6000
4000
2000
0
**
Pre-Lysate (n=6)
Post-Lysate (n=6)
B

FIGS. 4A-4B